subject area of
- A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial Journal Articles
- A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Journal Articles
- A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer Journal Articles
- Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture Journal Articles
- Association between timing of zoledronic acid infusion and hip fracture healing Journal Articles
- Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review Journal Articles
- Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care — Cancer Care Ontario Clinical Practice Guideline Journal Articles
- Changes in cross‐sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate) Journal Articles
- Clinical Risk Factors for Recurrent Fracture after Hip Fracture: A Prospective Study Journal Articles
- Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12 Journal Articles
- Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer Journal Articles
- Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study Journal Articles
- Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture Journal Articles
- Patient Management, and Time and Health Care Resource Utilization Associated with the Use of Intravenous Bisphosphonates For Patients with Metastatic Bone Disease: A Delphi Study Journal Articles
- Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study Journal Articles
- Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update Journal Articles
- Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture Journal Articles
- Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers Journal Articles
- The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair Journal Articles
- Time and Labor Costs Associated With Administration of Intravenous Bisphosphonates for Breast or Prostate Cancer Patients With Metastatic Bone Disease: A Time and Motion Study Journal Articles
- Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease Journal Articles
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline Journal Articles
- Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis Journal Articles
- Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis Journal Articles
- Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial Journal Articles